Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-05T09:38:14.514Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of IDO1 and TDO2 inhibition on cognitive deficits and anxiety following LPS-induced neuroinflammation

Published online by Cambridge University Press:  20 December 2019

Sophie Imbeault Open the ORCID record for Sophie Imbeault [Opens in a new window] ,
Michel Goiny ,
Xicong Liu  and
Sophie Erhardt
Sophie Imbeault
Affiliation:
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Michel Goiny
Affiliation:
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Xicong Liu
Affiliation:
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Sophie Erhardt*
Affiliation:
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
*
Author for correspondence: Sophie Erhardt, Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

Sustained immune activation leads to cognitive dysfunctions, depression-, and anxiety-like behaviours in humans and rodents. It is modelled by administration of lipopolysaccharides (LPS) to induce expression of pro-inflammatory cytokines that then activate indoleamine 2,3 dioxygenase (IDO1), the rate-limiting enzyme in the kynurenine pathway of tryptophan metabolism. Here, we ask whether chronic IDO1 inhibition by 1-methyl-tryptophan (1-MT, added at 2 g/l in the drinking water) or chronic inhibition of tryptophan 2,3 dioxygenase (TDO2), another enzyme capable of converting tryptophan to kynurenine, by 680C91 (15 mg/kg per os), can rescue LPS-induced (0.83-mg/kg intraperitoneally) anxiety and cognitive deficits. We also investigate the acute effects of 680C91 on serotonergic, dopaminergic, and kynurenine pathway metabolites.

Methods:

We examined LPS-induced deficits in trace fear conditioning and anxiety in the light–dark box and elevated plus maze (EPM) in group-housed C57Bl6/N mice. Kynurenine pathway metabolites and monoamine levels were measured via high-performance liquid chromatography.

Results:

Chronic blockade of IDO1 with 1-MT did not rescue cognitive deficits or abrogate the anxiogenic behaviour caused by LPS despite a decrease in the brain kynurenine:tryptophan ratio. However, 1-MT by itself demonstrated anxiolytic properties in the EPM. Acute and chronic inhibition of TDO2 elevated brain levels of tryptophan, while chronic inhibition of TDO2 was unsuccessful in rescuing cognitive deficits and abrogating the anxiety caused by LPS.

Conclusions:

In line with previous studies, we show that LPS administration induces anxiety and cognitive dysfunctions in mice that however were not reversed by chronic blockade of IDO1 or TDO2 at the doses used.

Keywords

lipopolysaccharideskynureninefear conditioning1-MT680C91
Type
Original Article
Information
Acta Neuropsychiatrica , Volume 32 , Issue 1 , February 2020 , pp. 43 - 53
Copyright
© Scandinavian College of Neuropsychopharmacology 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agudelo, LZ, Femenia, T, Orhan, F, Porsmyr-Palmertz, M, Goiny, M, Martinez-Redondo, V, Correia, JC, Izadi, M, Bhat, M, Schuppe-Koistinen, I, Pettersson, AT, Ferreira, DMS, Krook, A, Barres, R, Zierath, JR, Erhardt, S, Lindskog, M and Ruas, JL (2014) Skeletal muscle PGC-1alpha1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell 159(1), 33–45.CrossRefGoogle ScholarPubMed
Amori, L, Guidetti, P, Pellicciari, R, Kajii, Y and Schwarcz, R (2009) On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. Journal of Neurochemistry 109(2), 316–325.CrossRefGoogle ScholarPubMed
Campbell, BM, Charych, E, Lee, AW and Möller, T (2014) Kynurenines in CNS disease: regulation by inflammatory cytokines. Frontiers in Neuroscience 8, 12.CrossRefGoogle ScholarPubMed
Campos, AC, Fogaça, MV, Aguiar, DC and Guimarães, FS (2013) Animal models of anxiety disorders and stress. Brazilian Journal of Psychiatry 35(Suppl. 2), S101–S111.CrossRefGoogle Scholar
Capuron, L, Ravaud, A, Miller, AH and Dantzer, R (2004) Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behavior and Immunity 18(3), 205–213.CrossRefGoogle ScholarPubMed
Chess, AC, Simoni, MK, Alling, TE and Bucci, DJ (2007) Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophrenia Bulletin 33(3), 797–804.CrossRefGoogle ScholarPubMed
Dantzer, R (2001) Cytokine-induced sickness behavior: where do we stand? Brain Behavior and Immunity 15(1), 7–24.CrossRefGoogle ScholarPubMed
Dantzer, R, O’Connor, JC, Lawson, MA and Kelley, KW (2011) Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36(3), 426–436.CrossRefGoogle ScholarPubMed
Erhardt, S, Pocivavsek, A, Repici, M, Liu, XC, Imbeault, S, Maddison, DC, Thomas, MAR, Smalley, JL, Larsson, MK, Muchowski, PJ, Giorgini, F and Schwarcz, R (2017a) Adaptive and behavioral changes in kynurenine 3-monooxygenase knockout mice: relevance to psychotic disorders. Biological Psychiatry 82(10), 756–765.CrossRefGoogle ScholarPubMed
Erhardt, S, Schwieler, L, Imbeault, S and Engberg, G (2017b) The kynurenine pathway and schizophrenia. Neuropharmacology 112(Pt B), 297–306.CrossRefGoogle Scholar
Frick, A, Åhs, F, Engman, J, Jonasson, M, Alaie, I, Björkstrand, J, Frans, Ö, Faria, V, Linnman, C, Appel, L, Wahlstedt, K, Lubberink, M, Fredrikson, M and Furmark, T (2015) Serotonin synthesis and reuptake in social anxiety disorder: a positron emission tomography study. JAMA Psychiatry 72(8), 794–802.CrossRefGoogle ScholarPubMed
Gao, R, Kan, MQ, Wang, SG, Yang, RH and Zhang, SG (2016) Disrupted tryptophan metabolism induced cognitive impairment in a mouse model of sepsis-associated encephalopathy. Inflammation 39(2), 550–560.CrossRefGoogle Scholar
Gibney, SM, Fagan, EM, Waldron, AM, O’Byrne, J, Connor, TJ and Karkin, A (2014) Inhibition of stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal model of depressive behavior. International Journal of Neuropsychopharmacology 17(6), 917–928.CrossRefGoogle Scholar
Giorgini, F, Huang, SY, Sathyasaikumar, KV, Notarangelo, FM, Thomas, MAR, Tararina, M, Wu, HQ, Schwarcz, R and Muchowski, PJ (2013) Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. Journal of Biological Chemistry 288(51), 36554–36566.CrossRefGoogle ScholarPubMed
Hilmas, C, Pereira, EF, Alkondon, M, Rassoulpour, A, Schwarcz, R and Albuquerque, EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. Journal of Neuroscience 21(19), 7463–7473.CrossRefGoogle ScholarPubMed
Holtze, M, Mickiené, A, Atlas, A, Lindquist, L and Schwieler, L (2012) Elevated cerebrospinal fluid kynurenic acid levels in patients with tick-borne encephalitis. Journal of Internal Medicine 272(4), 394–401.CrossRefGoogle ScholarPubMed
Hou, DY, Muller, AJ, Sharma, MD, DuHadaway, J, Banerjee, T, Johnson, M, Mellor, AL, Prendergast, GC and Munn, DH (2007) Inhibition of 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Research 67(2), 792–801.CrossRefGoogle ScholarPubMed
Kim, JJ and Fanselow, MS (1992) Modality-specific retrograde amnesia. Science 256(5057), 675–677.CrossRefGoogle ScholarPubMed
Kozak, R, Campbell, BM, Strick, CA, Horner, W, Hoffmann, WE, Kiss, T, Chapin, DS, McGinnis, D, Abbott, AL, Roberts, BM, Fonseca, K, Guanowsky, V, Young, DA, Seymour, PA, Dounay, A, Hajos, M, Williams, GV and Castner, SA (2014) Reduction of brain kynurenic acid improves cognitive function. Journal of Neuroscience 34(32), 10592–10602.CrossRefGoogle ScholarPubMed
Larsson, MK, Faka, A, Bhat, M, Imbeault, S, Goiny, M, Orhan, F, Oliveros, A, Ståhl, S, Liu, XC, Choi, DS, Sandberg, K, Engberg, G, Schwieler, L and Erhardt, S (2016) Repeated LPS injection induces distinct changes in the kynurenine pathway in mice. Neurochemical Research 41(9), 2243–2255.CrossRefGoogle ScholarPubMed
Lawson, MA, McCusker, RH and Kelley, KW (2013b) Interleukin-1 beta converting enzyme is necessary for development of depression-like behavior following intracerebroventricular administration of lipopolysaccharide to mice. Journal of Neuroinflammation 10, 54.Google ScholarPubMed
Lawson, MA, Parrott, JM, McCusker, RH, Dantzer, R, Kelley, KW and O’Connor, JC (2013a) Intracerebroventricular administration of lipopolysaccharide induces indolamine-2,3-dioxygenase-dependent depression-like behaviors. Journal of Neuroinflammation 10, 87.CrossRefGoogle Scholar
Lestage, J, Verrier, D, Palin, K and Dantzer, R (2002) The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behavior and Immunity 16(5), 596–601.CrossRefGoogle ScholarPubMed
Liu, XC, Holtze, M, Powell, SB, Terrando, N, Larsson, MK, Persson, A, Olsson, SK, Orhan, F, Kegel, M, Asp, L, Goiny, M, Schwieler, L, Engberg, G, Karlsson, H and Erhardt, S (2014) Behavioral disturbances in adult mice following neonatal virus infection or kynurenine treatment – role of brain kynurenic acid. Brain Behavior and Immunity 36, 80–89.CrossRefGoogle ScholarPubMed
Miura, H, Shirokawa, T, Isobe, K and Ozaki, N (2009) Shifting the balance of brain tryptophan metabolism elicited by isolation housing and systemic administration of lipopolysaccharide in mice. Stress 12(3), 206–214.CrossRefGoogle ScholarPubMed
Möller, M, Du Preez, JL, Viljoen, FP, Berk, M, Emsley, R and Harvey, BH (2013) Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetylcysteine. Brain Behavior and Immunity 30, 156–167.CrossRefGoogle ScholarPubMed
O’Connor, JC, Lawson, MA, André, C, Moreau, M, Lestage, J, Castanon, N, Kelley, KW and Dantzer, R (2009) Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Molecular Psychiatry 14(5), 511–522.CrossRefGoogle ScholarPubMed
Painsipp, E, Köfer, MJ, Sinner, F and Holzer, P (2011) Prolonged depression-like behavior caused by immune challenge: influence of mouse strain and social environment. PLoS ONE 6(6), e20719.CrossRefGoogle ScholarPubMed
Perkins, MN and Stone, TW (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Research 247(1), 184–187.CrossRefGoogle ScholarPubMed
Polyzos, KA, Ovchinnikova, O, Berg, M, Baumgartner, R, Agardh, H, Pirault, J, Gisterå, A, Assinger, A, Laguna-Fernandez, A, Bäck, M, Hansson, GK and Ketelhuth, DF (2015) Inhibition of indoleamine 2,3-dioxygenase promotes vascular inflammation and increases atherosclerosis in Apoe-/- mice. Cardiovascular Research 106(2), 295–302.CrossRefGoogle Scholar
Potter, MC, Elmer, GI, Bergeron, R, Albuquerque, EX, Guidetti, P, Wu, HQ and Schwarcz, R (2010) Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 35(8), 1734–1742.CrossRefGoogle ScholarPubMed
Priteo, GA and Cotman, CA (2017) Cytokines and cytokine networks target neurons to modulate long-term potentiation. Cytokine & Growth Factor Reviews 34, 27–33.CrossRefGoogle Scholar
Pugh, CR, Kumagawa, K, Fleshner, M, Watkins, LR, Maier, SF and Rudy, JW (1998) Selective effects of peripheral lipopolysaccharide administration on contextual and auditory-cue fear conditioning. Brain Behavior and Immunity 12(3), 212–229.CrossRefGoogle ScholarPubMed
Salazar, A, Gonzalez-Rivera, BL, Redus, L, Parrott, JM and O’Connor, JC (2012) Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge. Hormones and Behavior 62(3), 202–209.CrossRefGoogle ScholarPubMed
Salter, M, Hazelwood, R, Pogson, CI, Iyer, R and Madge, DJ (1995) The effects of a novel and selective inhibitor of tryptophan 2,3-diozygenase on tryptophan and serotonin metabolism in the rat. Biochemical Pharmacology 49(10), 1435–1442.CrossRefGoogle ScholarPubMed
Sellgren, CM, Kegel, ME, Bergen, SE, Ekman, CJ, Olsson, S, Larsson, M, Vawter, MP, Backlund, L, Sullivan, PF, Sklar, P, Smoller, JW, Magnusson, PK, Hultman, CM, Walther-Jallow, L, Svensson, CI, Lichtenstein, P, Schalling, M, Engberg, G, Erhardt, S and Landén, M (2016) A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. Molecular Psychiatry 21(10), 1342–1350.CrossRefGoogle ScholarPubMed
Shimizu, T, Nomiyama, S, Hirata, F and Hayaishi, O (1978) Indoleamine 2,3-dioxygenase. Purification and some properties. Journal of Biological Chemistry 253(13), 4700–4706.Google ScholarPubMed
Skelly, DT, Hennessy, E, Dansereau, MA and Cunningham, C (2013) A systemic analysis of the peripheral and CNS effects of systemic LPS, IL-1beta, TNF-alpha and IL-6 challenges in C57BL/6 mice. PLoS ONE 8(7), e69123.CrossRefGoogle ScholarPubMed
Stone, TW and Darlington, LG (2013) The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. British Journal of Pharmacology 169(6), 1211–1227.CrossRefGoogle ScholarPubMed
Stone, TW and Perkins, MN (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. European Journal of Pharmacology 72(4), 411–412.CrossRefGoogle ScholarPubMed
Takikawa, O, Kuroiwa, T, Yamazaki, F and Kido, R (1988) Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. Journal of Biological Chemistry 263(4), 2041–2048.Google ScholarPubMed
Terrando, N, Rei Fidalgo, A, Vizcaychipi, M, Cibelli, M, Ma, D, Monaco, C, Feldmann, M and Maze, M (2010) The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction. Critical Care 14(3), R88 CrossRefGoogle ScholarPubMed
Too, LK, Li, KM, Suarna, C, Maghzal, GJ, Stocker, R, McGregor, IS and Hunt, NH (2016) Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive function. Behavioural Brain Research 312, 102–117.CrossRefGoogle ScholarPubMed
Varga, D, Herédi, J, Kànvàsi, Z, Ruszka, M, Kis, Z, Ono, E, Iwamori, N, Iwamori, T, Takakuwa, H, Vécsei, L, Toldi, J and Gellért, L (2015) Systemic L-kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57Bl/6 mice. Frontiers in Behavioral Neuroscience 9, 157.CrossRefGoogle ScholarPubMed
Wiedemann, K (2001) Anxiety and anxiety disorders. In Smelser, NJ and Baltes, PB (eds), International Encyclopedia of the Social & Behavioral Sciences. Pergamon: Oxford, pp. 560–567.CrossRefGoogle Scholar
Yi, SQ, Yang, M and Duan, KM (2015) Immune-mediated metabolic kynurenine pathways are involved in the postoperative cognitive dysfunction after cardiopulmonary bypass. Thoracic and Cardiovascular Surgeon 63(7), 618–623.CrossRefGoogle ScholarPubMed
Yirmiya, R (1996) Endotoxin produces a depressive-like episode in rats. Brain Research 711(1–2), 163–174.CrossRefGoogle ScholarPubMed
Supplementary material: Image

Imbeault et al. supplementary material

Imbeault et al. supplementary material

Download Imbeault et al. supplementary material(Image)
Image 156.3 KB